RESTATEMENT (Details 1) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Feb. 28, 2018 |
Feb. 28, 2017 |
Feb. 28, 2018 |
Feb. 28, 2017 |
Aug. 31, 2017 |
Aug. 31, 2016 |
|||||
Consolidated Statements of Operations | ||||||||||
Research and development | [1] | $ 647,467 | $ 680,543 | |||||||
Total Operating Expenses | 798,464 | [1] | $ 11,995 | 1,075,521 | [1] | $ 21,512 | $ 232,789 | $ 29,690 | ||
Loss from Operations | (798,464) | [1] | (11,995) | (1,075,521) | [1] | (21,512) | (232,789) | (29,690) | ||
NET LOSS | (798,464) | [1] | (13,011) | (1,075,521) | [1] | (22,528) | (234,889) | (29,690) | ||
TOTAL COMPREHENSIVE LOSS | $ (799,718) | [1] | $ (13,011) | $ (1,077,800) | [1] | $ (22,528) | $ (234,232) | $ (29,690) | ||
Basic and Diluted Loss per Common Share (in dollars per share) | $ (0.07) | [1] | $ (0.00) | $ (0.10) | [1] | $ (0.00) | $ (0.03) | $ (0.00) | ||
Originally Reported | ||||||||||
Consolidated Statements of Operations | ||||||||||
Research and development | $ 477,357 | $ 510,433 | ||||||||
Total Operating Expenses | 628,354 | 905,411 | ||||||||
Loss from Operations | (628,354) | (905,411) | ||||||||
NET LOSS | (628,354) | (905,411) | ||||||||
TOTAL COMPREHENSIVE LOSS | $ (629,608) | $ (907,690) | ||||||||
Basic and Diluted Loss per Common Share (in dollars per share) | $ (0.05) | $ (0.08) | ||||||||
Restatement Adjustment | ||||||||||
Consolidated Statements of Operations | ||||||||||
Research and development | $ 170,110 | $ 170,110 | ||||||||
Total Operating Expenses | 170,110 | 170,110 | ||||||||
Loss from Operations | (170,110) | (170,110) | ||||||||
NET LOSS | (170,110) | (170,110) | ||||||||
TOTAL COMPREHENSIVE LOSS | $ (170,110) | $ (170,110) | ||||||||
Basic and Diluted Loss per Common Share (in dollars per share) | $ (0.02) | $ (0.02) | ||||||||
|